KXCO's Model Books Are Three for Three on FDA Decisions, by Shayne Heffernan
KXCO's model books correctly predicted FDA decisions for three drugs: INO-3107 (approved), ivonescimab (refused), and deramiocel (refused). The books outperformed market indices and biotech ETFs. INO-3107's approval led to a 215% rise in Inovio's shares. Summit Therapeutics and Capricor saw declines after their drugs were refused.
How this was made

The 30-second read
Why it matters
The first‑report FDA approvals/denials provide fresh catalysts for the three biotech stocks, creating immediate trading opportunities.
Market read
The approvals/denials drive divergent moves in small‑cap biotech stocks, while the broader market remains down.
What to watch
Potential for future data releases or resubmissions could mitigate the impact of the denials.
Background
The article reviews KXCO's model books that correctly predicted three FDA outcomes, highlighting the predictive power of its methodology.
Ticker impact
Inovio received FDA accelerated approval for INO-3107 on 30 Oct 2026, a first report of the approval.
upward pressure as investors price in market potential
The approval was unexpected by the market and the stock already surged >200%; further upside remains as commercialization ramps.
Summit Therapeutics' ivonescimab was refused by the FDA on 15 Nov 2026, a first report of the denial.
downward pressure as the market absorbs the setback
The refusal was anticipated by the company’s own guidance; the stock fell 16.5% on the news.
Capricor Therapeutics' deramiocel was refused by the FDA on 20 Nov 2026, a first report of the denial.
downward pressure as investors reassess pipeline value
The company disclosed the complete response letter; similar biotech peers saw sharp declines after comparable setbacks.
Market effects
Biotech sector underperformed the market; XBI and IBB fell, but approvals can create relative outperformance for winners.
U.S. biotech stocks saw divergent moves; broader market indices declined.
FDA decisions are globally watched, influencing biotech sentiment worldwide.
Counterpoint
Some investors may view the INO surge as overbought and consider profit‑taking, while the denials could be priced in already.
Key entities
- companyInovio Pharmaceuticals
Developer of INO-3107, now FDA‑approved.
- companySummit Therapeutics
Developer of ivonescimab, FDA‑refused.
- companyCapricor Therapeutics
Developer of deramiocel, FDA‑refused.



